Introducing Signatera, a personalized, tumor-informed test

Signatera is a new blood test that can identify molecular residual disease, or recurrent cancer, sooner than existing methods, by detecting the presence of ctDNA. Signatera is a personalized, tumor-informed test optimized to detect ctDNA with high sensitivity and specificity. Revolutionizing cancer care begins with revolutionary testing. Learn more at nateraoncology.com